Belimumab With Rituximab for Primary Membranous Nephropathy

NCT ID: NCT03949855

Last Updated: 2025-09-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-03-06
• Study Completion Date: 2030-03-01

Brief Summary

The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.

Background:

Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.

Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.

Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.

In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.

Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.

Detailed Description

This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy (MN), ages 18-75 inclusive. The study will be conducted at multiple sites in the United States and Canada.

Part A: Open-label Phase

Part A is an open-label, PK study to compare belimumab exposure between participants who have "low" proteinuria (≥ 4 to < 8 g/day) and "high" proteinuria (≥ 8 g/day) at Visit -1.

Initially Part A planned to enroll 20 individuals with primary MN: 10 individuals with low proteinuria and 10 individuals with high proteinuria. All Part A participants received 200 mg subcutaneous belimumab weekly, the initially approved dose of belimumab in SLE, for 52 doses (weeks 0-51). Trough serum belimumab levels would be obtained weekly following the first 4 doses of belimumab. All participants would receive rituximab 1000 mg IV at weeks 4 and 6, and are followed after the 52 week treatment period on no study medication until week 156.

Belimumab trough levels were to be analyzed after all 20 participants received the first 4 doses to compare the belimumab exposure between the low and high proteinuria groups. If the belimumab exposure was not comparable between the high and low proteinuria groups, the belimumab dose would be doubled to 400 mg/weekly for participants with high proteinuria in Part B. Dose determination for participants with high proteinuria in Part B would be made by an adjudication committee comprised of the Protocol Chair, NIAID Medical Monitor, ITN Clinical Trial Physician, and Rho Scientist, in consultation with the belimumab PK expert at GSK.

Due in part to the observed imbalance in enrollment between the high and low proteinuria groups, an ad hoc PK analysis was conducted. The serum belimumab trough levels of the first 12 participants (8 with high proteinuria and 4 with low proteinuria) who received the first 4 belimumab doses were analyzed to compare belimumab exposure between the low and high proteinuria groups.

The results of the PK analysis were reviewed by the adjudication committee, who determined that the results did not support doubling the dose of belimumab in individuals with high proteinuria nor did it identify a new proteinuria threshold that warranted an increased belimumab dose. The belimumab PK expert at GSK concurred. Thus, enrollment into Part A has been suspended, and all participants in Part B are to receive the same dose of belimumab. All participants currently enrolled in Part A continue to receive belimumab and rituximab as previously planned and are undergoing the safety assessments as presented in Appendix A.

All enrolled participants in Part A will be followed until week 156 and will be assessed for the same study endpoints as participants in Part B.

Part B: Randomized Phase

Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN to assess the effectiveness of belimumab and rituximab at treating primary MN. Part B is commencing after the completion of the ad hoc PK analysis, which did not support increasing the belimumab dose in participants with high proteinuria.

A total of 58 participants will be randomized into two treatment arms.

Randomization will be stratified by low (≥ 4 to < 8 g/day) and high proteinuria (≥ 8 g/day). Eleven participants who entered Part B prior to protocol version 7.0 were randomized at a 1:1 ratio; 47 participants entering at or after protocol version 7.0 will be randomized at a 3:1 ratio. A total of 41 participants are projected to be enrolled in the belimumab and rituximab arm and 17 participants in the belimumab placebo and rituximab arm. The effectiveness of belimumab with rituximab will be evaluated using a hybrid control arm that combines participants who receive belimumab placebo and rituximab in this study and the subgroup of subjects with primary MN in the MENTOR trial who were anti-PLA2R positive at baseline and received rituximab alone. The randomized arms will also be used to evaluate the safety of adding belimumab to rituximab in primary MN and to support mechanistic studies.

Participants randomized to the belimumab and rituximab arm will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. This dosing regimen is based on the recommended dosing of subcutaneous belimumab for lupus nephritis. Participants randomized to the belimumab placebo and rituximab arm will receive subcutaneous belimumab placebo according to the same dose and schedule.

Participants in both arms will receive rituximab 1000 mg IV at weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and, defined as fulfilling at least two of the following three criteria at week 30, will receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

• Anti-PLA2R levels is ≥ 25% of baseline
• Proteinuria is ≥ 50% of baseline
• Serum albumin is < 2.8 g/dL

After the 52 week treatment period, all participants will be followed on no study medication with assessment of the primary endpoint (CR or PR) at week 104.

The primary endpoint will be assessed at week 104 because the proteinuric response to treatment is known to lag behind the active treatment period and is recommended to be assessed at least 18 months after the initiation of therapy. There will be a tolerance endpoint at week 156 to determine if treatment with belimumab with rituximab results in a more durable remission compared to rituximab alone, and to assess the rate of relapse after having achieved complete or partial remission.

Conditions

Membranous Nephropathy; Nephrotic Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Part A: Low Proteinuria Group - Belimumab and Rituximab

Open-label pharmacokinetics (PK) phase.

Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.

Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day).

Group Type: EXPERIMENTAL

Belimumab

Intervention Type: DRUG

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Rituximab

Intervention Type: DRUG

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

Part A :High Proteinuria Group - Belimumab and Rituximab

Open-label pharmacokinetics (PK) phase.

Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.

High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day).

Group Type: EXPERIMENTAL

Belimumab

Intervention Type: DRUG

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Rituximab

Intervention Type: DRUG

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

Part B: Belimumab and Rituximab

Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

• Anti-PLA2R level is ≥ 25% of baseline
• Proteinuria is ≥ 50% of baseline
• Serum albumin is < 2.8 g/dL

Group Type: EXPERIMENTAL

Belimumab

Intervention Type: DRUG

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Rituximab

Intervention Type: DRUG

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

Part B: Placebo and Rituximab

Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.

At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):

• Anti-PLA2R level is ≥ 25% of baseline
• Proteinuria is ≥ 50% of baseline
• Serum albumin is < 2.8 g/dL

Group Type: PLACEBO_COMPARATOR

Placebo for Belimumab

Intervention Type: DRUG

The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Standard weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Rituximab

Intervention Type: DRUG

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

Interventions

Belimumab

Belimumab is a recombinant, human, IgG1λ monoclonal antibody.

Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

Standard Weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Intervention Type: DRUG

Placebo for Belimumab

The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

Standard weekly dose:

Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.

Intervention Type: DRUG

Rituximab

Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.

Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.

Dose: 1000 mg intravenously (IV), Week 4 and -6.

Intervention Type: DRUG

Other Intervention Names

Benlysta®; Belimumab placebo; Rituxan®

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria to be eligible for this study-

1. Age 18 to 75 years inclusive

2. Diagnosis of one of the following:

1. Primary MN confirmed by a kidney biopsy within the past 5 years

2. Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years

3. Nephrotic syndrome with eGFR > 60 mL/min/1.73m2 and no history of immunosuppressant treatment (e.g. glucocorticoids, cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting agent) for nephrotic syndrome, and without evidence of a secondary cause of nephrotic syndrome

4. Nephrotic syndrome and a contraindication to kidney biopsy (e.g., anticoagulation, solitary kidney, body habitus that increases the risk of biopsy, or other contraindication in the opinion of the investigator), and without evidence of a secondary cause of nephrotic syndrome

3. Serum anti-PLA2R positive

4. eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade

5. Proteinuria:

1. ≥ 4 and < 8 g/day that has persisted for at least the previous 3 months while on maximally tolerated RAS blockade. Documentation of persistent proteinuria may be from a 24-hour collection or calculated from a spot urine collection. Or,

2. ≥ 8 g/day while on maximally tolerated RAS blockade

6. Blood pressure while on maximally tolerated RAS blockade:

1. Systolic blood pressure ≤ 140 mmHg

2. Diastolic blood pressure ≤ 90 mmHg

Exclusion Criteria

Subjects meeting any of the following criteria will not be eligible for this study-

1. Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation

2. Rituximab use within the previous 12 months

3. Rituximab use > 12 months ago:

1. With an undetectable CD19 B cell count, or

2. Did not result in a CR (Section 3.3.1) or PR (Section 3.3.2) with rituximab treatment alone (e.g., without other immunosuppressive or immunomodulatory therapy)

4. Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)

5. Cyclophosphamide use within the past 3 months

6. Use of other immunosuppressive medications such as cyclosporine or tacrolimus within the past 30 days

7. Use of systemic corticosteroids within the past 30 days

8. Use of any biologic investigational agent (defined as any drug not approved for sale in the country it is used) in the previous 12 months

9. Use of any non-biologic investigational agent in the past 30 days (or 5 half-lives, whichever is greater)

10. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 9.0%

11. Patients with diabetic glomerulopathy on renal biopsy that is:

1. Greater than Class I diabetic glomerulopathy, or

2. Class I diabetic glomerulopathy with a history of poor diabetic control (e.g., HbA1c ≥ 9.0%) since time of biopsy

12. Unstable kidney function defined as > 20% decrease in eGFR during the previous 3 months due to primary MN, as determined by the site investigator in consultation with the protocol chair

13. Decrease in proteinuria by 50% or more during the previous 12 months

14. WBC count < 3.0 x 103/μl

15. Absolute neutrophil count < 1.5 x 103/μl

16. Moderately severe anemia (hemoglobin < 9 g/dL)

17. History of primary immunodeficiency

18. Serum IgA < 10 mg/dL

19. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)

20. Positive HIV serology

21. Positive HCV serology, unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy)

22. Evidence of current or prior infection with hepatitis B, as indicated by positive HBsAg or positive HBcAb

23. Positive QuantiFERON - TB Gold test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold test

24. History of lung disease with FVC < 70% predicted, DLCO < 70% predicted, or requiring supplemental oxygen

25. History of malignant neoplasm within the last 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years

26. Absence of individualized, age-appropriate cancer screening

27. Women of child-bearing potential who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception until week 104

28. Acute or chronic infection, including current use of suppressive therapy for chronic infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection

29. History of an anaphylactic reaction or known sensitivity or intolerance to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies, including rituximab or belimumab

30. Evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk

31. Evidence of current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence in the past 12 months

32. Vaccination with a live vaccine within the past 30 days

33. Other diseases or conditions or other clinically significant abnormal laboratory value which in the opinion of the investigator would put the patient at risk or confound the results of the study

34. Inability to comply with study and follow-up procedures

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Immune Tolerance Network (ITN)

NETWORK

Sponsor Role: collaborator

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

PPD Development, LP

INDUSTRY

Sponsor Role: collaborator

Rho Federal Systems Division, Inc.

INDUSTRY

Sponsor Role: collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Patrick Nachman

Role: STUDY_CHAIR

University of Minnesota, Department of Medicine, Division of Renal Diseases and Hypertension

Iñaki Sanz

Role: STUDY_CHAIR

Emory University, Department of Medicine, Division of Rheumatology

Locations

University of Alabama at Birmingham School of Medicine: Division of Nephrology

Birmingham, Alabama, United States

Site Status: RECRUITING

University of Arkansas

Little Rock, Arkansas, United States

Site Status: RECRUITING

University of California San Francisco

San Francisco, California, United States

Site Status: RECRUITING

Stanford University School of Medicine: Division of Nephrology

Stanford, California, United States

Site Status: RECRUITING

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension

Torrance, California, United States

Site Status: RECRUITING

University of Colorado

Aurora, Colorado, United States

Site Status: RECRUITING

Mayo Clinic Jacksonville: Department of Nephrology and Hypertension

Jacksonville, Florida, United States

Site Status: RECRUITING

University of Miami Miller School of Medicine, Div of Nephrology

Miami, Florida, United States

Site Status: RECRUITING

Johns Hopkins

Baltimore, Maryland, United States

Site Status: RECRUITING

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Site Status: RECRUITING

University of Michigan

Ann Arbor, Michigan, United States

Site Status: RECRUITING

University of Minnesota Health Clinical Research Unit

Minneapolis, Minnesota, United States

Site Status: RECRUITING

Washington University in St. Louis

St Louis, Missouri, United States

Site Status: RECRUITING

University of Nebraska

Omaha, Nebraska, United States

Site Status: RECRUITING

Columbia University Medical Center: Division of Nephrology

New York, New York, United States

Site Status: RECRUITING

University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center

Chapel Hill, North Carolina, United States

Site Status: RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status: RECRUITING

Ohio State University Wexner Medical Center: Division of Nephrology

Columbus, Ohio, United States

Site Status: RECRUITING

University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division

Philadelphia, Pennsylvania, United States

Site Status: RECRUITING

Providence Medical Research Center, Providence Health Care: Nephrology

Spokane, Washington, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Maria El Hachem

Role: primary

mehachem@uabmc.edu

205-975-0549

Gail Runnells

Role: primary

RunnellsGailAnn@uams.edu

501-526-7956

Juan Espinoza

Role: primary

Juan.Espinoza@ucsf.edu

415-502-3618

Brittany Yeung

Role: primary

yeungb@stanford.edu

650-498-3116

Elizabeth Chen

Role: backup

echen15@stanford.edu

Janine LaPage

Role: primary

jlapage@lundquist.org

310-222-4104

Jenny Santa Rosa

Role: primary

jennyleigh.santarosa@cuanschutz.edu

303-724-7790

Elizabeth Wagner

Role: backup

elizabeth.c.wagner@cuanschutz.edu

303-724-1647

Tia Wilkes

Role: primary

wilkes.quantia@mayo.edu

904-953-3636

Marialby D Ramos

Role: primary

mxd4514@med.miami.edu

Carlos Bidot

Role: backup

cbidot2@med.miami.edu

305-243-8793

Kristin Lyman

Role: primary

klyman1@jh.edu

734-276-1248

Lilian V. Howard, CRNP

Role: primary

howardlv@mail.nih.gov

301-594-0298

Jennifer DeLuca

Role: primary

delucaj@med.umich.edu

734-936-0369

Brady Wallner

Role: primary

walln080@umn.edu

612-626-3415

Michelle Bloom

Role: primary

mbloom@wustl.edu

314-286-0875

Tammy Jones, RN

Role: primary

tamjones@unmc.edu

402-559-4335

Anup Pradhan

Role: primary

arp2209@cumc.columbia.edu

212-305-5037

Anne Froment

Role: primary

anne_froment@med.unc.edu

919-445-2622

Sandra Hodnick

Role: primary

hodnics@ccf.org

216-444-0124

Laci Roberts

Role: primary

laci.roberts@osumc.edu

614-685-5323

Krishna Kallem, MD, MPH

Role: primary

Krishna.Kallem@pennmedicine.upenn.edu

484-358-0315

Nicole Maser, MSH, RN

Role: primary

nicole.maser@providence.org

509-474-5315

References

Ayoub I, Nachman PH. Advances in ANCA-associated vasculitis and lupus nephritis. Nat Rev Nephrol. 2021 Feb;17(2):89-90. doi: 10.1038/s41581-020-00388-x. No abstract available.

Reference Type: DERIVED

PMID: 33311560 (View on PubMed)

Related Links

https://www.niaid.nih.gov/

National Institute of Allergy and Infectious Diseases (NIAID)

https://www.niaid.nih.gov/about/dait

Division of Allergy, Immunology, and Transplantation (DAIT)

http://www.immunetolerance.org

Immune Tolerance Network (ITN)

http://reboot-study.org/

Visit this ITN Study website for more information

Other Identifiers

NIAID CRMS ID#:38478

Identifier Type: OTHER

Identifier Source: secondary_id

DAIT ITN080AI

Identifier Type: -

Identifier Source: org_study_id